Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma

A M Schram; P Jonsson; A Drilon; T A Bale; J F Hechtman; R Benayed; B Hanusch; R J Young; C Grommes; N Ku; T Kaley; D M Hyman; B S Taylor

doi:10.1200/PO.18.00089

Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma

JCO Precis Oncol. 2018:2:PO.18.00089. doi: 10.1200/PO.18.00089. Epub 2018 Aug 8.

Authors

A M Schram^{1

2

3}, P Jonsson^{4

5

3}, A Drilon^{1

2}, T A Bale⁶, J F Hechtman⁶, R Benayed⁶, B Hanusch⁷, R J Young⁸, C Grommes⁹, N Ku¹⁰, T Kaley⁹, D M Hyman^{1

2}, B S Taylor^{4

5

11}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Weill Cornell Medical College, New York, NY.
³ These authors contributed equally to this work.
⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
⁵ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁷ Clinical Research Administration, Memorial Sloan Kettering Cancer Center, New York, NY.
⁸ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁹ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
¹⁰ Loxo Oncology, Stamford, CT.
¹¹ Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Grants and funding